关键词：关节炎；肌肉骨骼；诊断测试；检查病情；止痛药；抗抑郁药；镇静药
摘 要：The National Institute of Arthritis and Musculoskeletal and Skin Diseases states that fibromyalgia is a condition of unknown etiology. Unlike arthritis, the condition does not cause inflammation of the joints, muscles, or other tissues but leads to their impairment, resulting in chronic pain, muscle tenderness, and fatigue in individuals. There is no particular diagnostic test for fibromyalgia. Physicians perform differential diagnosis to check the presence of the condition in suspected individuals. Women are more susceptible to the condition than men. The condition affects more than five million people aged 18 and above in the US, with women accounting for 80-90% of the total number of affected individuals, as reported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases in 2014. Currently, only three drugs have been approved to treat fibromyalgia in the US. Off-label drugs such as analgesics, antidepressants, sedatives, neuroleptics, and muscle relaxants are used to treat the condition, especially in EMEA and APAC.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Product Profiles

04.1.1 Savella

04.1.2 Cymbalta

04.1.3 Lyrica

05. Market Research Methodology

05.1 Market Research Process

05.2 Research Methodology

06. Introduction

07. Disease Overview

07.1 Understanding the Disease

07.2 Signs and Symptoms

07.2.1 Pain and Muscle Stiffness

07.2.2 Sleep Disturbances

07.2.3 Fatigue

07.2.4 Chronic Headache

07.2.5 Other Symptoms

07.3 Epidemiology

07.4 Pathophysiology

07.5 Economic Burden

07.6 Novel Therapeutic Approach

08. Market Landscape

08.1 Market Overview

08.2 Market Size and Forecast

08.3 Fibromyalgia Drugs Market in US

08.3.1 Market Overview

08.3.2 Market Size and Forecast

08.4 Fibromyalgia Drugs Market in Europe

08.4.1 Market Overview

08.4.2 Market Size and Forecast

08.5 Five Forces Analysis

09. Market Segmentation by Chemical Class of

Drug

09.1 Global Fibromyalgia Drugs Market by Chemical

Class of Drug 2014-2019

09.2 Serotonin-norepinephrine Reuptake Inhibitors

09.3 GABA Analogs

09.4 Others

10. Geographical Segmentation

10.1 Global Fibromyalgia Drugs Market by Geography

2014-2019

11. Buying Criteria

12. Pipeline Portfolio

12.1 Key Information on Pipeline Candidates

12.1.1 TNX-102 SL

12.1.2 Lyrica CR

12.1.3 DS-5655

12.1.4 TD-9855

12.1.5 IMC-1

12.1.6 Mirtazapine

12.1.7 Flupirtine

12.1.8 SWT06101

12.1.9 ZYN001

13. Market Growth Drivers

14. Drivers and Their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and Their Impact

19. Vendor Landscape

19.1 Competitive Scenario

19.1.1 Key News

19.1.2 Mergers and Acquisitions

19.2 Major Vendor Analysis 2014

19.2.1 Pfizer

19.2.2 Eli Lilly

19.2.3 Actavis

19.3 Other and Future Prominent Vendors

20. Key Vendor Analysis

20.1 Actavis

20.1.1 Key Facts

20.1.2 Business Description

20.1.3 Business Segmentation

20.1.4 Business Segmentation by Revenue 2012 and 2013

20.1.5 Sales by Geography

20.1.6 Business Strategy

20.1.7 Key Information

20.1.8 SWOT Analysis

20.2 Eli Lilly

20.2.1 Key Facts

20.2.2 Business Overview

20.2.3 Business Segmentation by Revenue

20.2.4 Sales by Geography

20.2.5 Business Strategy

20.2.6 Key Information

20.2.7 SWOT Analysis

20.3 Pfizer

20.3.1 Key Facts

20.3.2 Business Overview

20.3.3 Business Segmentation by Revenue 2014

20.3.4 Business Segmentation by Revenue 2013 and 2014

20.3.5 Geographical Segmentation by Revenue 2014

20.3.6 Business Strategy

20.3.7 Key Developments

20.3.8 SWOT Analysis

21. Other Reports in This Series